Amorfix has developed a core expertise in the field of protein misfolding with its ability to identify regions on proteins that are unique in a diseased state and not in a normal healthy state.
Amorfix's Therapeutics are designed to target and neutralize only the misfolded conformation of a given protein. This allows proteins that are correctly folded to continue their normal function.
Amorfix provides Diagnostic Services using its highly sensitive and specific Diagnostic Kits to Alzheimer's researchers and prion removal equipment manufacturers. Amorfix also provides custom assay development services.
Early Diagnosis and Treatment
Alzheimer's Disease (AD), Amyotrophic Lateral Sclerosis (ALS) and Parkinson's Disease (PD) are chronic neurodegenerative illnesses which are associated with deposits of AMPs. Unlike the TSE (prion) diseases, these diseases are not thought to be infectious and it is believed that their AMPs result from abnormal synthesis or metabolism of the normal brain proteins. The only definitive diagnostic for these diseases is postmortem examination of brain tissue. There are currently 5 million people in North America with AD and an equal number with dementia which may be suffering from AD but it is impossible to diagnose due to a lack of a blood test. Worldwide there are 460 million people over the age of 65 who should be tested annually for AD now that therapies are available. The worldwide market for a blood-based diagnostic test would be more than US$1 billion annually and has been estimated to be as high as US$5 billion.
The focus on misfolded proteins represents an entirely new approach to the identification of cancer targets and may allow for the development of very selective therapeutics offering greater efficacy with reduced toxicity. Amorfix's strategy to identify novel DSE's on well-validated targets using the ProMIS™ technology will attempt to solve these problems by producing highly selective and potent proprietary therapeutics with greater efficacy and safety, thereby greatly reducing the risk of failure.